TCT.18 | 合法醫療器材資訊網

2018年9月27日—25,morphedintoadiscussionaboutthefutureofbioresorbablevascularscaffolds(BVS)andwhetherit'sworthpursuingbioresorbablestent ...

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

The comments stemmed from the presentations of one-year results from ABSORB IV[1] and COMPARE-ABSORB, both of which found Abbott’s Absorb BVS was statistically noninferior to the company’s Xience drug-eluting stent (DES) for the primary endpoint of target-lesion failure (TLF). However, the BVS in both cases was linked to more cases of TLF (7.8 percent versus 6.4 percent in ABSORB IV; 5.1 percent versus 4.2 percent in COMPARE-ABSORB) and device thrombosis (0.7 percent vs. 0.3 percent in ABSORB IV; 2.0 versus 0.6 percent in COMPARE-ABSORB).

The Absorb stents were pulled from the commercial market[2] last year but ...